Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

5.615 -0.085 (-1.49%)

Streaming Delayed Price Updated: 3:47 PM EST, Feb 9, 2026 Add to My Watchlist

Price and Volume

Volume	3,733,513
Open	5.720
Bid (Size)	5.610 (1,600)
Ask (Size)	5.620 (7,600)
Prev. Close	5.700
Today's Range	5.310 - 5.918
52wk Range	1.540 - 9.750
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Today 8:00 EST

From Nuvation Bio

Via Business Wire

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Nuvation Bio

Via Business Wire

Performance

YTD	-34.6%	-34.6%
1 Month	-30.2%	-30.2%
3 Month	+21.0%	+21.0%
6 Month	+150.7%	+150.7%
1 Year	+146.3%	+146.3%

More News

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

January 12, 2026

From Nuvation Bio and Eisai

Via Business Wire

Nuvation Bio Stock Logs Its Best Session Ever: Wall Street Turns Bullish On Lung Cancer Drug’s Blockbuster Debut ↗

November 20, 2025

Via Stocktwits

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Nuvation Bio

Via Business Wire

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

December 03, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Participate in Upcoming Investor Conferences

November 26, 2025

From Nuvation Bio

Via Business Wire

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

4 Analysts Assess Nuvation Bio: What You Need To Know ↗

September 30, 2025

Via Benzinga

Analyst Expectations For Nuvation Bio's Future ↗

September 08, 2025

Via Benzinga

Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance

November 19, 2025

Via MarketMinute

Which stocks are moving on Wednesday? ↗

November 19, 2025

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

November 19, 2025

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 19, 2025

Via Benzinga

Nuvation Bio (NUVB) Q3 2025 Earnings Transcript ↗

November 04, 2025

Via The Motley Fool

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

November 03, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock ↗

November 03, 2025

Via The Motley Fool

Nuvation Bio to Participate in Upcoming Investor Conferences

October 30, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

October 23, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

October 20, 2025

From Nuvation Bio

Via Business Wire

Why Nuvation Bio Stock Is Skyrocketing Today ↗

September 30, 2025

Via The Motley Fool

United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗

September 30, 2025

Via Benzinga

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

September 30, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

September 19, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

September 07, 2025

From Nuvation Bio

Via Business Wire

Frequently Asked Questions

Is Nuvation Bio Inc. Class A Common Stock publicly traded?

Yes, Nuvation Bio Inc. Class A Common Stock is publicly traded.

What exchange does Nuvation Bio Inc. Class A Common Stock trade on?

Nuvation Bio Inc. Class A Common Stock trades on the New York Stock Exchange

What is the ticker symbol for Nuvation Bio Inc. Class A Common Stock?

The ticker symbol for Nuvation Bio Inc. Class A Common Stock is NUVB on the New York Stock Exchange

What is the current price of Nuvation Bio Inc. Class A Common Stock?

The current price of Nuvation Bio Inc. Class A Common Stock is 5.615

When was Nuvation Bio Inc. Class A Common Stock last traded?

The last trade of Nuvation Bio Inc. Class A Common Stock was at 02/09/26 03:47 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.